Oncology testing services company NeoGenomics Inc (NASDAQ: NEO) announced on Wednesday that it will present three key studies at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona from 13-17 September. The studies emphasise the value of circulating tumour DNA (ctDNA) analysis and next-generation sequencing (NGS) in advancing early cancer detection and personalised treatment.

Among the highlights, data from a real-world analysis show NGS testing for multiple gene fusions can identify four times more patients eligible for matched therapies than traditional methods. Another study on ctDNA in early-stage non-small cell lung cancer (NSCLC) pinpoints patients at high relapse risk, guiding more aggressive treatment strategies. A third trial explores ctDNA as a marker to inform treatment in high-risk melanoma, comparing combined anti-LAG-3 and anti-PD-1 therapies with anti-PD-1 alone.

NeoGenomics, headquartered in Fort Myers, FL, is a leader in cancer genetics testing, offering comprehensive services for healthcare providers and pharmaceutical clients across multiple certified laboratories in the US and UK.